Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Thirteen new fluorine-containing drugs, which have been granted approval by the US Food
and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of …
and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of …
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
[PDF][PDF] LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or …
N Katakami, S Atagi, K Goto, T Hida, T Horai, A Inoue… - J Clin …, 2013 - med.kindai.ac.jp
Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
Diarrhea associated with afatinib: an oral ErbB family blocker
Gastrointestinal (GI) adverse events (AEs) are frequently observed in patients receiving EGF
receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase inhibitor therapy. GI AEs are …
receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase inhibitor therapy. GI AEs are …
Consumer willingness to purchase hydrogen fuel cell vehicles: A meta-analysis of the literature
W Wang, J Li, Y Li - International Journal of Hydrogen Energy, 2023 - Elsevier
Hydrogen fuel cell vehicles (HFCVs), as an important strategic path for global sustainable
development and energy transition, have now become an important support for the global …
development and energy transition, have now become an important support for the global …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
J Aguilar-Company, M Fernández-Ruiz… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
[HTML][HTML] Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy
K Domvri, P Zarogoulidis, K Darwiche… - Journal of …, 2013 - ncbi.nlm.nih.gov
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …